Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

81
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
81
Autoimmune Disorders01:29

Autoimmune Disorders

2.0K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.0K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

15.2K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
15.2K
Rh Blood Group01:19

Rh Blood Group

3.9K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
3.9K
Blood Typing01:10

Blood Typing

3.3K
Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...
3.3K
Blood Transfusion01:15

Blood Transfusion

2.7K
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape.

Clinical advances in hematology & oncology : H&O·2025
Same author

Complement inhibitors: a significant advance in the treatment of PNH.

Clinical advances in hematology & oncology : H&O·2025
Same author

Monotherapy with terminal pathway C5 inhibitors.

Clinical advances in hematology & oncology : H&O·2025
Same author

Practical approach to managing PNH: Q&A.

Clinical advances in hematology & oncology : H&O·2025
Same author

Thrombosis in immune thrombocytopenia.

Clinical advances in hematology & oncology : H&O·2025
Same author

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.

Blood·2025
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

31.3K

Autoimmune Hemolytic Anemia.

Howard A Liebman1, Ilene C Weitz1

  • 1Jane Anne Nohl Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

The Medical Clinics of North America
|February 13, 2017
PubMed
Summary
This summary is machine-generated.

Autoimmune hemolytic anemia occurs when antibodies attack red blood cells, shortening their survival. Treatment focuses on immune modulation using corticosteroids and other agents to manage this acquired autoimmune disorder.

Keywords:
AnemiaAutoantibodiesHemolysis

More Related Videos

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

10.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

31.3K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

10.0K

Area of Science:

  • Hematology
  • Immunology
  • Internal Medicine

Background:

  • Autoimmune hemolytic anemia (AIHA) is an acquired autoimmune condition.
  • Antibodies target red blood cell (erythrocyte) antigens, leading to premature cell destruction.
  • AIHA can be idiopathic or secondary to other conditions like malignancies or infections.

Purpose of the Study:

  • To provide a concise overview of autoimmune hemolytic anemia.
  • To highlight the underlying pathophysiology and clinical presentations.
  • To summarize current therapeutic strategies.

Main Methods:

  • Review of existing literature on AIHA.
  • Analysis of diagnostic criteria and clinical manifestations.
  • Synthesis of treatment modalities.

Main Results:

  • AIHA involves autoantibody production against erythrocytes.
  • Erythrocyte survival is significantly reduced.
  • Disease presentation varies from primary to secondary forms.

Conclusions:

  • AIHA is a complex autoimmune disorder requiring targeted immune modulation.
  • Corticosteroids are a primary treatment modality.
  • Management strategies are tailored to disease severity and underlying causes.